Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

BioLife Solutions reports preliminary Q4 and full-year results

EditorRachael Rajan
Published 09/01/2024, 12:22 am
© Reuters.
BLFS
-

BOTHELL, Wash. - BioLife Solutions, Inc. (NASDAQ: NASDAQ:BLFS), a key player in bioproduction for cell and gene therapies, disclosed preliminary unaudited financial results for the fourth quarter and full year of 2023. The company experienced an 11% sequential increase in cell processing revenue for the fourth quarter, reaching $14.8 million, while overall revenue saw a 26% decline from the same quarter the previous year.

The company's total preliminary revenue for the fourth quarter was reported at $32.7 million, a decrease from the $44.3 million in the fourth quarter of 2022. The decline is partly attributed to a decrease in COVID-related revenue, which fell by $9.5 million or 22%. Despite this, the cell processing platform showed a sequential rise from the third quarter of 2023.

For the full year of 2023, BioLife Solutions posted a revenue of $143.3 million, marking an 11% decrease from the $161.8 million reported in 2022. The cell processing platform's annual revenue was down 4%, totaling $65.8 million.

Roderick de Greef, Chairman and CEO of BioLife, expressed a cautious optimism for the easing of macro and inventory headwinds. He highlighted the company's role in the cell and gene therapy market, noting that BioLife's products are integrated into 14 approved therapies, with the potential for inclusion in 10 more by the end of the year.

The company also mentioned the ongoing divestiture of its freezer business, which is anticipated to conclude within the quarter, aiming to enhance BioLife's financial profile by focusing on its higher-margin, recurring cell processing business.

Further details on the company's financial performance and outlook will be provided during the fourth quarter and year-end 2023 earnings call scheduled for February.

This report is based on a press release statement from BioLife Solutions, Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.